300006 莱美药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.064-0.425-3.210-6.042-23.960
总资产报酬率 ROA (%)0.046-0.300-2.297-3.310-9.829
投入资产回报率 ROIC (%)0.055-0.360-2.799-4.112-12.272

边际利润分析
销售毛利率 (%)65.09769.33073.49871.46668.089
营业利润率 (%)-3.5046.278-10.857-5.725-21.856
息税前利润/营业总收入 (%)1.632-2.123-7.963-7.057-16.340
净利润/营业总收入 (%)2.302-1.119-8.624-8.646-21.765

收益指标分析
经营活动净收益/利润总额(%)-183.610-2,145.438151.840119.26051.999
价值变动净收益/利润总额(%)-57.4032,421.015-7.682-45.226-0.983
营业外收支净额/利润总额(%)180.175-1,464.312-27.63133.806-0.724

偿债能力分析
流动比率 (X)2.5542.9282.4892.5900.997
速动比率 (X)2.3062.6242.2012.3530.823
资产负债率 (%)26.92326.59128.48324.41860.874
带息债务/全部投入资本 (%)11.33311.57914.8407.79046.932
股东权益/带息债务 (%)771.888735.392568.4871,157.97599.850
股东权益/负债合计 (%)265.792270.667244.128301.73661.128
利息保障倍数 (X)-0.5960.841-14.654-4.432-3.049

营运能力分析
应收账款周转天数 (天)148.842131.612153.285133.152127.609
存货周转天数 (天)227.901244.692276.541233.973218.488